An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study

Inclusion Criteria:

- Female patients ≥ 18 years old with histologically confirmed Stage III or IV
epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in
CAN-003

- Able and willing to undergo MNC collection (if required for patients who do not have
available Cvac doses)

- Were enrolled in CAN-003 and met protocol criteria for progressive disease

- Wish to remain in the study and, in the investigator's judgment, the potential
benefit of Cvac treatment outweighs the risk

- Must be non-pregnant and, if of childbearing potential, must use adequate birth
control (hormonal or barrier method of birth control or abstinence) for the duration
of the study and for 3 months after study completion

- Able to provide written informed consent

- White blood cell count (WBC) ≥ 3.0 K/μL, absolute neutrophil count ≥ 1.5 K/μL,
hemoglobin ≥ 9.0 g/dL, and platelets ≥100,000/mm3

Exclusion Criteria:

- Pregnant or breastfeeding

- Other medical conditions which preclude study participation, in the opinion of the
investigator

- Receiving treatment with any other investigational product